SCNLF
Scancell Holdings plc
SCNLF
Scancell Holdings plc
Scancell Holdings PLC (AIM:SCLP, OTC:SCNLF, FRA:SCP), the cancer immunotherapy developer, has won UK regulatory approval to run a late-stage trial of its lead drug in advanced melanoma. The Medicines
Scancell Holdings PLC (AIM:SCLP, OTC:SCNLF, FRA:SCP), the Oxford-based cancer immunotherapy developer listed on London's junior AIM market, has agreed an all-share merger with US biotech Neuphoria The